A registry for metastatic colorectal cancer beyond second line
Part of Cancer, Digestive system clinical trials.
This study tracks people with metastatic colorectal cancer who have already tried at least two standard treatments. It aims to collect real-world data on how well newer treatments work in later lines of therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with colorectal cancer that has spread (metastatic).
- You have already received at least two different types of chemotherapy or targeted therapy for your cancer.
- If you received a specific strong chemo combo as your first treatment, you may enter the registry after just one prior line.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
This trial tests regorafenib as a second-line treatment for people with advanced colorectal cancer that has a RAS mutation. It aims to see if this targeted therapy can help when the first treatment stopped working.
This study looks at different chemotherapy options for people with metastatic colorectal cancer that has stopped responding to first treatment. It aims to find which second-line approach works best.
This study collects health information from patients with cancer that has spread to the liver. Researchers will track your medical history and outcomes to better understand how metastatic liver cancer develops and progresses.
This trial tests a combination of radiation therapy, an immunotherapy drug (QL1706), and two targeted drugs (TAS-102 and bevacizumab) for people with advanced colorectal cancer that has spread and is not removable by surgery. It aims to see if this combination can help shrink tumors or slow cancer growth.
This study collects health and treatment information from people with breast cancer that cannot be fully removed by surgery or that has spread to other parts of the body. It may help researchers better understand which treatments are used and how people do over time.
Hear when a new Metastatic Colorectal Cancer (mCRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.